title: Neurochemical investigation of the schizophrenic brain by in vivo phosphorus magnetic resonance spectroscopy.
abstract: Abnormal phospholipid metabolisms may play important roles in the pathophysiology of schizophrenia. Phosphorus magnetic resonance spectroscopy (31P-MRS) offers a new method for studying phosphorus-related metabolism in vivo. A decrease in the level of phosphomonoesters (PME) and an increase in the level of phosphodiesters (PDE) has been demonstrated in the prefrontal lobe of neuroleptic-naive schizophrenic patients. Most of the studies in medicated schizophrenic patients have shown decreased PME and/or increased PDE. The decreased PME in the frontal lobe appears to be associated with negative symptoms and poor working memory performance. 1H-decoupled 31P-MRS revealed a reduction in the phosphocholine element of PME and an elevation in the mobile phospholipids of PDE in the prefrontal region of medicated schizophrenic patients. PDE were elevated in the temporal lobes of neuroleptic-naive schizophrenic patients, and this increase was partially normalized by haloperidol administration. Data about the temporal lobes of medicated schizophrenic patients have not been consistent. Except for the reduction in the adenosine triphosphate (ATP) in the basal ganglia and the correlation between the increase in the frontal lobe phosphocreatine (PCr) and negative symptomatology, data related to changes in high-energy phosphates are contradictory. No consensus on the effect of neuroleptics on phosphorus metabolites has been achieved. Methodological problems inherent in 31P-MRS may have contributed to the confusion in understanding available data. Future directions of MRS studies are suggested in the last section of the paper.
authors.affiliation: Department of Neuropsychiatry, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan. fukuzako@med4.kufm.kagoshima-u.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Fukuzako
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology*; D005625:Frontal Lobe / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D010725:Phosphocreatine / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D010744:Phosphoric Monoester Hydrolases / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology*; D013702:Temporal Lobe / Q000378:metabolism / Q000503:physiopathology
chemical_list: D014150:Antipsychotic Agents; D010743:Phospholipids; D010725:Phosphocreatine; D010744:Phosphoric Monoester Hydrolases; D010727:Phosphoric Diester Hydrolases